Ask AI
ProCE Banner Activity

Optimizing Neoadjuvant Treatment in HER2+ Early-Stage Breast Cancer

Slideset

Neoadjuvant therapy has evolved into a platform for prognosis, treatment selection, and therapeutic innovation in HER2-positive breast cancer. These slides review the evidence for removing anthracyclines from routine neoadjuvant treatment, eliminating carboplatin, and potentially replacing chemotherapy with targeted treatments. The current landscape of personalized neo/adjuvant treatment selection relies on factors including initial disease burden, previous treatments, and residual disease burden.

Released: October 08, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for oncologists, advanced practice providers, nurse practitioners, clinical nurse specialists, nurses, pharmacists, and other health care professionals who care for patients with HER2-positive breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select appropriate neoadjuvant HER2-targeted regimens for patients with HER2-positive early breast cancer using clinical factors such as tumor size, nodal status, and hormone receptor expression